Ligand releases positive data on Avinza for pain reduction

By Elaine Rigoli

Tampa, Fla., May 4 - Ligand Pharmaceuticals, Inc. announced the final data from three studies of its pain product Avinza that indicated the product showed better around-the-clock control of chronic pain and improved sleep in a large randomized study comparing Avinza given once daily to oxycodone CR given twice daily in patients with low back pain.

A second study demonstrated Avinza's ability to provide better sleep as well as improved pain control for patients with moderate-to-severe chronic osteoarthritis, according to a news release.

In the third study conducted in patients with chronic, non-cancer, moderate-to-severe pain, Avinza was shown to improve pain, sleep and physical functioning, the release said.

Avinza is a once-a-day treatment for chronic moderate-to-severe pain in patients who require continuous, around-the-clock opioid therapy for an extended period of time.

San Diego-based Ligand develops drugs in the areas of cancer, pain, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.